NY-THREATNG
28.2.2023 15:01:42 CET | Business Wire | Press release
ThreatNG, a cybersecurity company dedicated to empowering organizations of all sizes to manage their external attack surface and digital risks, has announced the release of its agentless Cloud and SaaS Exposure Assessment Module. The company also announced free access to organizations to this groundbreaking platform to assess their external risk for a limited time.
The ThreatNG “Cloud and SaaS Exposure” Module supports the following vendors and technology categories:
- Amazon Web Services (AWS)
- Microsoft Azure
- Google Cloud Platform (GCP)
- Analytics
- Business Intelligence (BI)
- Customer Relationship Management (CRM)
- File Sharing
- Human Resources
- Security
- Video Telephony
ThreatNG continues to redefine External Attack Surface Management (EASM), Digital Risk Protection, and Security Ratings by announcing the availability of its Agentless Cloud and SaaS Exposure Assessment Module. Requiring only a domain and organization name, ThreatNG users can perform Outside-In Discovery, Assessment, Reporting, and Monitoring of their Cloud and SaaS Footprint, uncover Exposed Open Cloud Buckets, bring to light Unsanctioned Implementations (Shadow IT), and call to attention Brand Impersonations (Cybersquats) without using agents, credentials, API connections, browser plugins, and any other means that require prior knowledge.
ThreatNG further empowers its users by providing a differentiated, unmatched, and holistic approach by extending discovery and assessment of all Internet-exposed online applications, repositories, APIs, platform-as-a-service (PaaS), infrastructure-as-a-service (IaaS), and vendor technologies interconnected with Cloud and SaaS implementations.
“As more critical data and functions are migrating to the cloud, it becomes much more important for organizations to have visibility of all their digital assets exposed to the public and address all potential risks and threats. Our Cloud and SaaS Exposure module empower users with a proactive outside-in perspective,” said Eric Gonzales, founder of ThreatNG. “We are so confident in our technology’s capability that we are willing to provide organizations of all sizes with a free discovery and risk assessment of their Cloud and SaaS environments.”
To learn more about ThreatNG and its Cloud and SaaS Exposure Assessment capabilities, visit the company’s website, www.threatngsecurity.com/cloudexposure.
Cloud and SaaS Environments are continuously evolving. With new instances appearing, this constant change makes it challenging to keep an accurate inventory of sanctioned implementations and maintain good cyber hygiene overall. This growing Cloud and SaaS sprawl feeds into the ever-increasing problem of Shadow IT (Unsanctioned Implementations) and Cybersquats (Brand Impersonations). This uncontrollable sprawl has also led to increased security risks and exposures, a growth in phishing attacks abusing SaaS platforms, and cloud assets compromised more than on-premise assets (Verizon 2022 Data Breach Investigations Report).
Cloud and SaaS Impersonations (Cybersquats) and Exposed Data within Open Cloud Buckets are growing problems with organizations of all sizes and their Third Parties. Still, they are out of scope within most External Attack Surface Management (EASM), Digital Risk Protection, and Security Rating Services. ThreatNG unites these solution capabilities and empowers users to seamlessly bring Cloud and SaaS into the fold of Asset Inventory, Security & Governance, Subsidiary Security Monitoring, Third-Party Security Assessments, and Brand Protection through their innovative external discovery and assessment requiring only a domain and organization name.
Support for all of the above is available today and accompanied by all of the following investigation modules provided to all ThreatNG users:
- Domain Intelligence
- Technology Stack
- Sensitive Code Exposure
- Online Sharing Exposure
- Search Engine Exploitation
- Sentiment and Financials
- Archived Web Pages
- Social Media
- Dark Web
Contact ThreatNG Security today for a Free 30-Day Evaluation of their Cloud and SaaS Exposure Assessment Module.
About ThreatNG
ThreatNG is redefining external attack surface management (EASM), digital risk protection, and security ratings with a platform of unmatched breadth, depth, and capabilities in managing technical and business threats across the dark, deep, and open web. Living up to the company mantra (“Security Centric; Not Exclusive”), ThreatNG provides a configurable solution to target, discover, and assess digital assets across a definable ecosystem of organizations, subsidiaries, partners, third parties, supply chains, and customers. Bolstered and maintained by the open source intelligence (OSINT) experts at DarcSight Labs, ThreatNG empowers organizations of all types and sizes to uncover, understand, and manage their external digital threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005863/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom